TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34321583

Group type: EXPERIMENTAL
Intervention: Regorafenib administered for > 3 weeks
Number of subjects: 613
Study: 34321836

Group type: EXPERIMENTAL
Intervention: HLX01 (a rituximab biosimilar)
Number of subjects: 99

Group type: COMPARATOR
Intervention: rituximab-CN (reference rituximab)
Number of subjects: 99
Study: 34321880

Group type: EXPERIMENTAL
Intervention: Cognitive tasks for individuals with gambling disorder (GbD)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cognitive tasks for individuals with gaming disorder (GmD)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cognitive tasks for individuals with sexual addiction (SA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cognitive tasks for individuals with food addiction (FA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 120
Study: 34321921

Group type: EXPERIMENTAL
Intervention: MPS-HA2% (single injection)
Number of subjects: 101
Study: 34321944

Group type: EXPERIMENTAL
Intervention: Semi-individualized traditional acupuncture (TA)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Noninvasive sham acupuncture (SA)
Number of subjects: 140
Study: 34322077

Group type: EXPERIMENTAL
Intervention: Robotic Priming of Bilateral Approach
Number of subjects: 0
Study: 34322089

Group type: EXPERIMENTAL
Intervention: Attachment style and social support interventions, details not available
Number of subjects: 0
Study: 34322164

Group type: EXPERIMENTAL
Intervention: Suprachoroidal injection of triamcinolone acetonide suspension (CLS-TA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic or locally administered corticosteroids
Number of subjects: 0
Study: 34322460

Group type: EXPERIMENTAL
Intervention: SafeBoosC-III Consortium intervention
Number of subjects: 0
Study: 34322463

Group type: EXPERIMENTAL
Intervention: Radiographic lung area measurement
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: sPAP measurement
Number of subjects: 77
Study: 34322775

Group type: EXPERIMENTAL
Intervention: Copanlisib (45 mg and 30 mg intravenously on days 1, 8, and 15 of 28-day cycles) in combination with cetuximab (standard doses of 400 mg/m weekly)
Number of subjects: 0
Study: 34322918

Group type: EXPERIMENTAL
Intervention: Extravascular ICD (EV ICD) system
Number of subjects: 400
Study: 34323296

Group type: EXPERIMENTAL
Intervention: Cushing's syndrome (CS) patients with sarcopenia
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cushing's syndrome (CS) patients without sarcopenia
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cushing's syndrome (CS) patients
Number of subjects: 36

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 36
Study: 34323406

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoimmunotherapy
Number of subjects: 29
Study: 34323413

Group type: EXPERIMENTAL
Intervention: Injection of collagenase Clostridium histolyticum (CCH) at high doses (0.1-0.2 mg/cm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verteporfin and nintedanib (FDA-approved drugs)
Number of subjects: 0
Study: 34323526

Group type: EXPERIMENTAL
Intervention: Technology-assisted education program; median time of 91 min to complete.
Number of subjects: 0
Study: 34323541

Group type: EXPERIMENTAL
Intervention: Perceived discrimination (PD)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Just-in-time adaptive interventions (JITAIs)
Number of subjects: 169
Study: 34323851

Group type: EXPERIMENTAL
Intervention: Epidemic-Pandemic Impacts Inventory (EPII) survey
Number of subjects: 245
Study: 34323955

Group type: EXPERIMENTAL
Intervention: Weekly isoniazid and rifapentine (3HP) at standard doses (900 mg/week)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Weekly isoniazid and rifapentine (3HP) in pregnant women with HIV
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Weekly isoniazid and rifapentine (3HP)
Number of subjects: 50
Study: 34323957

Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Number of subjects: 2620

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 2620
Study: 34323958

Group type: EXPERIMENTAL
Intervention: R-CHOP (Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: G-CHOP (Obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 0
Study: 34324028

Group type: EXPERIMENTAL
Intervention: Niraparib 300 mg single dose
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg daily (MHI)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg or 300 mg based on weight and platelets (NHF)
Number of subjects: 17
Study: 34324046

Group type: EXPERIMENTAL
Intervention: Modified formula feeding with MFGM components
Number of subjects: 44

Group type: COMPARATOR
Intervention: Breast milk feeding
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: In vitro growth experiment with MFGM components (lactadherin, sialic acid, phospholipid)
Number of subjects: 44
Study: 34324166

Group type: EXPERIMENTAL
Intervention: Spectralis SD-OCT
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Optovue SD-OCT
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: All three OCT instruments
Number of subjects: 272
Study: 34324392

Group type: EXPERIMENTAL
Intervention: Anti-CD7 CAR T cells, single infusion at a dose of 5 × 10
Number of subjects: 20
Study: 34324441

Group type: EXPERIMENTAL
Intervention: Autologous polyclonal Tregs followed by one or two 5-day courses of recombinant human low-dose IL-2 (ld-IL-2)
Number of subjects: 0
Study: 34324451

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) initiated in the first week of life
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Defective sequences
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Intact sequences
Number of subjects: 257
Study: 34324500

Group type: EXPERIMENTAL
Intervention: Stunted children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal nutritional status children
Number of subjects: 0
Study: 34324524

Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: COVID-19 negative patients
Number of subjects: 0
Study: 34324628

Group type: EXPERIMENTAL
Intervention: Various interventions to improve recruitment (e.g., increasing recruitment sites, providing extra time, communication training for study staff, redesigning patient information)
Number of subjects: 7612

Group type: EXPERIMENTAL
Intervention: Measures to improve retention (e.g., maintaining close contact with participants, showing appreciation, reimbursing travel arrangements)
Number of subjects: 7612
Study: 34324909

Group type: COMPARATOR
Intervention: Baseline Go/Nogo (non-reward incentivized/control)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Reward incentivized Go/Nogo (food, money)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Eating in the absence of hunger (EAH)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Reward trials (food vs. money)
Number of subjects: 66
Study: 34325107

Group type: EXPERIMENTAL
Intervention: Neoadjuvant or conversion chemotherapy
Number of subjects: 52
Study: 34325453

Group type: EXPERIMENTAL
Intervention: Lifestyle modification (improving restful sleep, exercise, eating at regulated mealtimes, avoiding dietary triggers) for at least 60 days
Number of subjects: 28
Study: 34325523

Group type: EXPERIMENTAL
Intervention: Home discharge
Number of subjects: 3460

Group type: COMPARATOR
Intervention: Nonhome discharge
Number of subjects: 3460
Study: 34325696

Group type: EXPERIMENTAL
Intervention: Community-based, peer-led and incentivised SRH intervention
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Prevention points cards (PPC) for incentivising service use
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Community-based spaces (hubs) for service delivery
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Training and characteristics of service providers
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Engagement process with AYP
Number of subjects: 230
Study: 34325710

Group type: EXPERIMENTAL
Intervention: Home-based physical exercises monitoring alone
Number of subjects: 122

Group type: COMPARATOR
Intervention: Combined physical exercises monitoring with home-based cognitive training
Number of subjects: 122
Study: 34325726

Group type: EXPERIMENTAL
Intervention: 7 × 19 CAR-T cells (anti-GPC3-7 × 19 CAR-T)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7 × 19 CAR-T cells (anti-MSLN-7 × 19 CAR-T)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional CAR-T cells
Number of subjects: 0
Study: 34325853

Group type: EXPERIMENTAL
Intervention: Comprehensive AI Retinal Expert (CARE) system
Number of subjects: 207228
Study: 34326007

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived mesenchymal stem cells (BMSCs)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Phosphodiesterase type 5 inhibitors (PDE5Is)
Number of subjects: 10
Study: 34326100

Group type: EXPERIMENTAL
Intervention: Worsening kidney function (WKF) defined as an estimated glomerular filtration rate (eGFR) decline greater than 40% from baseline.
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Medium-high cardiovascular risk group
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Worsening kidney function (WKF) event
Number of subjects: 10251
Study: 34326179

Group type: EXPERIMENTAL
Intervention: First 1000 Days program
Number of subjects: 995

Group type: COMPARATOR
Intervention: Usual care (comparison centers)
Number of subjects: 995
Study: 34326187

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study: 34326188

Group type: EXPERIMENTAL
Intervention: Omalizumab (anti-IgE) treatment
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: C4Ma3 degradation marker
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Fulacimstat (chymase inhibitor)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: C4Ma3 levels
Number of subjects: 405
Study: 34326800

Group type: EXPERIMENTAL
Intervention: Promoting Alternative Thinking Strategies (PATHS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34326839

Group type: EXPERIMENTAL
Intervention: Neoantigen reactive T cells combined with tomotherapy
Number of subjects: 1
Study: 34326905

Group type: EXPERIMENTAL
Intervention: OCTA (Optical Coherence Tomography Angiography)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 40
Study: 34326920

Group type: EXPERIMENTAL
Intervention: Six-month walking intervention with activity tracker
Number of subjects: 49
Study: 34327136

Group type: EXPERIMENTAL
Intervention: Penpulimab (200 mg i.v. Q3W) plus Anlotinib (8 mg/day, 2 weeks on/1 week off)
Number of subjects: 31
Study: 34327207

Group type: EXPERIMENTAL
Intervention: Multivitamins (MV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34327344

Group type: EXPERIMENTAL
Intervention: Iguratimod (IGU) 25 mg bid as monotherapy or to background therapy
Number of subjects: 1759

Group type: EXPERIMENTAL
Intervention: Iguratimod (IGU) 25 mg bid
Number of subjects: 1759
Study: 34327406

Group type: EXPERIMENTAL
Intervention: Detachable string magnetically controlled capsule endoscopy (DS-MCCE)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Esophagogastroduodenoscopy (EGD)
Number of subjects: 105
Study: 34327411

Group type: EXPERIMENTAL
Intervention: Sphincter preservation surgery
Number of subjects: 342

Group type: COMPARATOR
Intervention: Abdominoperineal resection
Number of subjects: 342
Study: 34327510

Group type: EXPERIMENTAL
Intervention: Nonablative, Noncoagulative Multipolar Radiofrequency and Pulsed Electromagnetic Field Treatment
Number of subjects: 0
Study: 34327561

Group type: EXPERIMENTAL
Intervention: dd-ABVD (dose-dense ABVD)
Number of subjects: 96
Study: 34327604

Group type: EXPERIMENTAL
Intervention: Standardized Aronia melanocarpa extract (SAE) 30 ml/day for 30 days
Number of subjects: 30
Study: 34327735

Group type: EXPERIMENTAL
Intervention: LWYY model
Number of subjects: 8399

Group type: EXPERIMENTAL
Intervention: Cox model
Number of subjects: 8399

Group type: EXPERIMENTAL
Intervention: Mao-Lin model
Number of subjects: 8399

Group type: EXPERIMENTAL
Intervention: Recurrent event models
Number of subjects: 8399
Study: 34327883

Group type: EXPERIMENTAL
Intervention: Underweight group (<18.5 kg/m²)
Number of subjects: 2914

Group type: COMPARATOR
Intervention: Normal weight group (18.5-25 kg/m²)
Number of subjects: 2914

Group type: EXPERIMENTAL
Intervention: Overweight group (25-30 kg/m²)
Number of subjects: 2914

Group type: EXPERIMENTAL
Intervention: Obese group (≥30 kg/m²)
Number of subjects: 2914
Study: 34328338

Group type: EXPERIMENTAL
Intervention: Novel method for determining HER2 expression
Number of subjects: 0
Study: 34328394

Group type: EXPERIMENTAL
Intervention: Chronic medical and psychiatric conditions (cluster 1: heart condition, hypertension, liver problems; cluster 2: gastrointestinal problems, head injury; cluster 3: anxiety disorder, bipolar disorder, schizophrenia)
Number of subjects: 1646

Group type: EXPERIMENTAL
Intervention: Bipolar disorder, liver problems, and individuals with one chronic condition
Number of subjects: 1646

Group type: EXPERIMENTAL
Intervention: Heart condition, hypertension, and GI problems
Number of subjects: 1646

Group type: EXPERIMENTAL
Intervention: Anxiety disorder, head injury, individuals with one or more than two psychiatric conditions, and individuals with more than two chronic conditions
Number of subjects: 1646
Study: 34328428

Group type: EXPERIMENTAL
Intervention: Psychoeducation plus mindfulness training
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Psychoeducation, mindfulness training, and additional modules targeting maladaptive behavioral avoidance
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (Psychoeducation plus mindfulness training)
Number of subjects: 80
Study: 34328438

Group type: EXPERIMENTAL
Intervention: Safe Step program (self-managed digital fall prevention exercise program)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Safe Step program
Number of subjects: 25
Study: 34328563

Group type: EXPERIMENTAL
Intervention: Glabellar tap sign (GR) in patients with Parkinson's disease (PD)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Glabellar tap sign (GR) in patients with essential tremor (ET)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Glabellar tap sign (GR) in healthy controls
Number of subjects: 161
Study: 34329317

Group type: EXPERIMENTAL
Intervention: Risk score model based on 6 independent predictors of mortality (age, respiratory rate ≥25/minute, oxygenation <94%, hypertension, coronary artery disease, chronic renal disease)
Number of subjects: 3123

Group type: EXPERIMENTAL
Intervention: Risk score model
Number of subjects: 3123

Group type: EXPERIMENTAL
Intervention: Online calculator of 40-day COVID-19 mortality risk score
Number of subjects: 3123
Study: 34329401

Group type: EXPERIMENTAL
Intervention: Women with paroxysmal AF
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Men with paroxysmal AF
Number of subjects: 364
Study: 34329436

Group type: EXPERIMENTAL
Intervention: Subjective health measures (general health, role physical function, physical function)
Number of subjects: 2783

Group type: EXPERIMENTAL
Intervention: Time-varying effects modeling (TVEM)
Number of subjects: 2783

Group type: EXPERIMENTAL
Intervention: Role physical function and physical function
Number of subjects: 2783

Group type: EXPERIMENTAL
Intervention: General health
Number of subjects: 2783
Study: 34329576

Group type: EXPERIMENTAL
Intervention: Venetoclax added to CLIA (cladribine, high-dose cytarabine, idarubicin)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group not applicable (single-arm trial)
Number of subjects: 50
Study: 34329772

Group type: EXPERIMENTAL
Intervention: PRESERFLO® MicroShunt with adjunctive use of topical mitomycin C (MMC; 0.2-0.4 mg/ml) for 2-3 minutes
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: PRESERFLO® MicroShunt with adjunctive use of topical mitomycin C (MMC; 0.2 mg/ml)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: PRESERFLO® MicroShunt with adjunctive use of topical mitomycin C (MMC; 0.4 mg/ml)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: PRESERFLO® MicroShunt
Number of subjects: 81
Study: 34329846

Group type: EXPERIMENTAL
Intervention: Budigalimab 375 mg via intravenous infusion every 3 weeks plus Rova-T 0.3 mg/kg intravenously on day 1 of the first and third 3-week cycle
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Budigalimab plus Rova-T in patients with high delta-like protein 3 expression
Number of subjects: 31
Study: 34329939

Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg b.i.d. + intravenous pegylated liposomal doxorubicin (PLD) 40 mg/m²
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PLD 30 mg/m²
Number of subjects: 31
Study: 34330322

Group type: EXPERIMENTAL
Intervention: Paquinimod 3 mg/day for 8 weeks
Number of subjects: 9
Study: 34330416

Group type: EXPERIMENTAL
Intervention: ESC/ESA algorithm classification in a higher-risk group
Number of subjects: 6976

Group type: COMPARATOR
Intervention: Overuse or underuse of cardiac tests
Number of subjects: 6976

Group type: COMPARATOR
Intervention: Test recommendation class for cardiac tests
Number of subjects: 6976
Study: 34330417

Group type: EXPERIMENTAL
Intervention: Standardized Assessment of Global activities in the Elderly (SAGE) scale
Number of subjects: 152
Study: 34330671

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) applications targeting the atrial edge of the leak, average 18 ± 7 RF applications per patient, mean maximum contact force 16 ± 3 g, mean power 44 ± 2 W, mean RF time 5.1 ± 2.5 minutes.
Number of subjects: 43
Study: 34330715

Group type: EXPERIMENTAL
Intervention: Neoadjuvant FOLFIRINOX × 8
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Chemoradiation with carboplatin/paclitaxel
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Surgical resection after neoadjuvant treatment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pathologic complete response (pCR)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA (ctDNA) analysis
Number of subjects: 25
Study: 34330766

Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (TVEC) with concurrent preoperative external beam radiation therapy (EBRT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (EBRT alone)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Postoperative outcomes
Number of subjects: 30
Study: 34330786

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 1457

Group type: COMPARATOR
Intervention: Other basal insulins
Number of subjects: 1457
Study: 34330792

Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID)
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Functional iron deficiency (ID)
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Iron deficiency anaemia (ID anaemia)
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Iron deficiency in untreated patients
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Iron deficiency in non-anaemic patients
Number of subjects: 1221
Study: 34330842

Group type: EXPERIMENTAL
Intervention: ASTX029, a dual-mechanism ERK inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASTX029
Number of subjects: 0
Study: 34330906

Group type: EXPERIMENTAL
Intervention: ChAdOx1 Chik vaccine (single intramuscular injection at one of three preestablished dosages)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ChAdOx1 Chik vaccine (single intramuscular injection)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ChAdOx1 Chik vaccine
Number of subjects: 24
Study: 34330970

Group type: EXPERIMENTAL
Intervention: Sauna dehydration (loss of 3% body weight)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drug (NSAID) intake
Number of subjects: 20

Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 20
Study: 34331019

Group type: EXPERIMENTAL
Intervention: SARS-CoV2 CONFIRMED infection
Number of subjects: 331

Group type: COMPARATOR
Intervention: SARS-CoV2 SUSPECTED infection
Number of subjects: 331
Study: 34331051

Group type: EXPERIMENTAL
Intervention: CoronaVac vaccine in ARD group
Number of subjects: 1092

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 1092
Study: 34331111

Group type: EXPERIMENTAL
Intervention: Bortezomib in combination with fludarabine plus cyclophosphamide (B-FC)
Number of subjects: 40
Study: 34331258

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 60 mg
Number of subjects: 622
Study: 34331265

Group type: EXPERIMENTAL
Intervention: Symptomatic patients with ATTR amyloidosis
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Symptomatic Val30Met patients
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Symptomatic ATTRwt patients
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: All symptomatic patients
Number of subjects: 379
Study: 34331515

Group type: EXPERIMENTAL
Intervention: BRAF and MEK inhibitors
Number of subjects: 2
Study: 34331548

Group type: EXPERIMENTAL
Intervention: Whole-body computed tomography (WBCT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dual energy X-ray absorptiometry (DXA)
Number of subjects: 10
Study: 34331588

Group type: EXPERIMENTAL
Intervention: COPD Assessment Test (CAT) item 1 (cough)
Number of subjects: 2046

Group type: EXPERIMENTAL
Intervention: COPD Assessment Test (CAT) item 2 (phlegm)
Number of subjects: 2046

Group type: EXPERIMENTAL
Intervention: COPD Assessment Test (CAT) item 5 (activities)
Number of subjects: 2046

Group type: EXPERIMENTAL
Intervention: mMRC dyspnea scale
Number of subjects: 2046

Group type: EXPERIMENTAL
Intervention: Functional parameters and comorbidities
Number of subjects: 2046

Group type: EXPERIMENTAL
Intervention: Item 8 (energy) in men
Number of subjects: 2046

Group type: EXPERIMENTAL
Intervention: mMRC in men
Number of subjects: 2046

Group type: EXPERIMENTAL
Intervention: Smoking status in men
Number of subjects: 2046

Group type: EXPERIMENTAL
Intervention: BMI in men
Number of subjects: 2046

Group type: EXPERIMENTAL
Intervention: Age in men
Number of subjects: 2046

Group type: EXPERIMENTAL
Intervention: Spirometric lung function in men
Number of subjects: 2046

Group type: EXPERIMENTAL
Intervention: Age in women
Number of subjects: 2046
Study: 34331589

Group type: EXPERIMENTAL
Intervention: Anamorelin 100 mg orally daily with standardized physical activity and nutrition counseling for 43 days
Number of subjects: 45
Study: 34332113

Group type: EXPERIMENTAL
Intervention: Subclinical remodeling investigation
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Increased tissue gene expression
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Plasma levels of COL8A2 and TNC
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Gene panel including tissue KCNJ2, COL1A1, COL8A2, and EDN1
Number of subjects: 150